BioMarin Pharmaceutical Inc. on Target for Its 15% Revenue Growth Goal

BioMarin Pharmaceutical Inc. on Target for Its 15% Revenue Growth Goal

It was a solid third quarter for BioMarin Pharmaceutical (NASDAQ: BMRN) as the biotech keeps plugging along, increasing sales of its orphan drugs while making progress on its pipeline drug candidates.

Metric

Q3 2017

Continue reading

Source: Fool.com